Publications

This retrospective study directly addresses the real-world integration of metastasis-directed external beam radiation therapy (M-EBRT) with 177Lu-PSMA-617 (LuPSMA) radioligand therapy in patients with advanced castration-resistant prostate cancer. For a researcher entering this field, it provides practical clinical data on how these two modalities are combined, including timing, indications, tolerability, and PSA response - all critical for understanding current translational practice.

Key finding: M-EBRT was used alongside LuPSMA in 20% of patients primarily for intracranial/epidural disease and bone palliation, was well tolerated, and provided symptom relief in 62% of cases, supporting its role as an adjunct to radioligand therapy.

KLK2 and STEAP1 are emerging cell surface targets for radioligand therapy and antibody-drug conjugate approaches in prostate cancer. This integrative molecular profiling study characterizes their expression across metastatic castration-resistant prostate cancer subtypes, defines co-expression with PSMA, and maps regulatory mechanisms - directly informing target selection and patient stratification for next-generation radioligand therapy trials.

Key finding: KLK2 and STEAP1 are co-expressed with PSMA in androgen receptor-positive metastatic castration-resistant prostate cancer, with high combined positivity rates suggesting that cotargeting any two of these antigens increases overall tumor coverage.